Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Larimar Therapeutics stock

LRMR
US5171251003
A2P5PP

Price

6.55
Today +/-
-0.02
Today %
-0.30 %
P

Larimar Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Larimar Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Larimar Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Larimar Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Larimar Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Larimar Therapeutics Stock Price History

DateLarimar Therapeutics Price
9/30/20246.55 undefined
9/27/20246.57 undefined
9/26/20246.33 undefined
9/25/20246.34 undefined
9/24/20246.41 undefined
9/23/20246.48 undefined
9/20/20247.07 undefined
9/19/20247.14 undefined
9/18/20246.85 undefined
9/17/20246.81 undefined
9/16/20246.69 undefined
9/13/20247.20 undefined
9/12/20247.24 undefined
9/11/20247.48 undefined
9/10/20247.89 undefined
9/9/20247.54 undefined
9/6/20248.05 undefined
9/5/20248.90 undefined
9/4/20247.77 undefined
9/3/20246.92 undefined

Larimar Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Larimar Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Larimar Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Larimar Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Larimar Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Larimar Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Larimar Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Larimar Therapeutics’s growth potential.

Larimar Therapeutics Revenue, EBIT and net profit per share

DateLarimar Therapeutics RevenueLarimar Therapeutics EBITLarimar Therapeutics Net Income
2029e346.65 M undefined0 undefined0 undefined
2028e223.82 M undefined-80.12 M undefined-189.4 M undefined
2027e101.74 M undefined-138.38 M undefined-222.59 M undefined
2026e21.04 M undefined-154.29 M undefined-158.88 M undefined
2025e0 undefined-130.76 M undefined-131.18 M undefined
2024e0 undefined-82.61 M undefined-91.93 M undefined
20230 undefined-41.76 M undefined-36.95 M undefined
20220 undefined-36.53 M undefined-35.36 M undefined
20210 undefined-50.47 M undefined-50.64 M undefined
20200 undefined-42.8 M undefined-42.48 M undefined
20190 undefined-40.1 M undefined-45.41 M undefined
20180 undefined-61.12 M undefined-61.37 M undefined
20170 undefined-53 M undefined-52.03 M undefined
20160 undefined-58.23 M undefined-57.88 M undefined
20150 undefined-73.81 M undefined-74.29 M undefined
20140 undefined-35.53 M undefined-36.57 M undefined
20130 undefined-13.78 M undefined-14.24 M undefined
20120 undefined-13.79 M undefined-13.95 M undefined
20110 undefined-13.15 M undefined-13.21 M undefined

Larimar Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
00000000000000021101223346
----------------380.95120.7955.16
-------------------
0000000000000000000
-13-13-13-35-73-58-53-61-40-42-50-36-41-82-130-154-138-800
----------------733.33-136.63-35.87-
-13-13-14-36-74-57-52-61-45-42-50-35-36-91-131-158-222-1890
--7.69157.14105.56-22.97-8.7717.31-26.23-6.6719.05-30.002.86152.7843.9620.6140.51-14.86-
1.731.731.731.022.232.272.292.693.1111.8817.1625.7643.9000000
-------------------
Details

Keystats

ⓘ

Revenue and Growth

The Larimar Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Larimar Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (k)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (k)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
201220132014201520162017201820192020202120222023
                       
9.935.5115.5185.1129.2102.1118.170.392.670.1118.486.79
000000000000
000000000000
000000000000
0.40.21.31.71.41.91.715.31.92.33.39
10.335.7116.8186.8130.6104119.871.397.972120.790.18
000.10.90.70.50.47.954.53.73.76
000000000000
60000000000000
000000000000
000000000000
00.70.20.10.10.10.11.41.8222
0.60.70.310.80.60.59.36.86.55.75.76
10.936.4117.1187.8131.4104.6120.380.6104.778.5126.495.94
                       
62.8103.80000000000.04
0.10.3209.8349359.3367.8444.2449.9155.3180.6262.5270.15
-54.9-68.9-105.4-179.7-237.5-289.6-350.9-396.4-65.6-116.3-151.6-188.55
000-200-100-1000000081
000000000000
835.2104.4169.1121.778.193.353.589.764.3110.981.72
1.222.37.52.633.60.62.61.71.71.28
1.70.93.26.13.74.34.34.36.47.298.22
000000000000
00004000000000
001.42.93.205.57.30000
2.92.96.916.59.97.313.412.298.910.79.51
006.23.502015.28.50000
000000000000
00000006.565.44.84.71
006.23.502015.21565.44.84.71
2.92.913.1209.927.328.627.21514.315.514.22
10.938.1117.5189.1131.6105.4121.980.7104.778.6126.495.93
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Larimar Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Larimar Therapeutics's financial health and stability.

Assets

Larimar Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Larimar Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Larimar Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Larimar Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (k)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2011201220132014201520162017201820192020202120222023
-13-13-14-36-74-57-52-61-45-42-50-35-36
0000000000000
0000000000000
00-136-5000-221-2
00057118944101213
00000001,0001,0000000
0000000000000
-12-13-15-28-59-51-43-51-40-42-42-27-33
0000000000000
000-57-925135-6251724-9033
000-57-915235-6261724-9033
0000000000000
0507-1-2160-50000
101640103131006707519750
102240108129-21666-59319750
000-20000018000
0000000000000
-282522-22-388-20681-430
-12.31-13.59-15.02-28.3-60.15-52.64-43.84-51.6-41.54-42.26-42.44-27.67-33.62
0000000000000

Larimar Therapeutics stock margins

The Larimar Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Larimar Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Larimar Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Larimar Therapeutics's sales revenue. A higher gross margin percentage indicates that the Larimar Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Larimar Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Larimar Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Larimar Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Larimar Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Larimar Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Larimar Therapeutics Margin History

Larimar Therapeutics Gross marginLarimar Therapeutics Profit marginLarimar Therapeutics EBIT marginLarimar Therapeutics Profit margin
2029e0 %0 %0 %
2028e0 %-35.8 %-84.62 %
2027e0 %-136.01 %-218.79 %
2026e0 %-733.24 %-755.04 %
2025e0 %0 %0 %
2024e0 %0 %0 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %
20150 %0 %0 %
20140 %0 %0 %
20130 %0 %0 %
20120 %0 %0 %
20110 %0 %0 %

Larimar Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Larimar Therapeutics earnings per share therefore indicates how much revenue Larimar Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Larimar Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Larimar Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Larimar Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Larimar Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Larimar Therapeutics Revenue, EBIT and net profit per share

DateLarimar Therapeutics Sales per ShareLarimar Therapeutics EBIT per shareLarimar Therapeutics Earnings per Share
2029e5.43 undefined0 undefined0 undefined
2028e3.51 undefined0 undefined-2.97 undefined
2027e1.59 undefined0 undefined-3.49 undefined
2026e0.33 undefined0 undefined-2.49 undefined
2025e0 undefined0 undefined-2.06 undefined
2024e0 undefined0 undefined-1.44 undefined
20230 undefined-0.95 undefined-0.84 undefined
20220 undefined-1.42 undefined-1.37 undefined
20210 undefined-2.94 undefined-2.95 undefined
20200 undefined-3.6 undefined-3.58 undefined
20190 undefined-12.89 undefined-14.6 undefined
20180 undefined-22.72 undefined-22.81 undefined
20170 undefined-23.14 undefined-22.72 undefined
20160 undefined-25.65 undefined-25.5 undefined
20150 undefined-33.1 undefined-33.31 undefined
20140 undefined-34.83 undefined-35.85 undefined
20130 undefined-7.97 undefined-8.23 undefined
20120 undefined-7.97 undefined-8.06 undefined
20110 undefined-7.6 undefined-7.64 undefined

Larimar Therapeutics business model

Larimar Therapeutics Inc is a US biotechnology company focused on developing therapies for rare genetic diseases. It was founded in 2018 and is based in Philadelphia, Pennsylvania. The company's mission is to accelerate the development of therapies for patients with rare genetic diseases through collaboration with academic researchers, patient organizations, and industry partners. They are active in various therapeutic areas, including neurological diseases, genetic metabolic disorders, and rare inherited diseases, with a diverse portfolio of drug candidates in different stages of clinical development. Their main focus is on developing therapies for Friedreich's ataxia, a rare neurological disease, and other neurologic disorders. They are also working on therapies for rare genetic metabolic disorders such as PKU and HFI. Larimar Therapeutics aims to improve the quality of life for patients with rare inherited diseases and adopts an innovative and patient-centered approach to their drug development. Collaborations and partnerships are integral to their strategy in order to make faster progress in the treatment of these often severe diseases. Larimar Therapeutics is one of the most popular companies on Eulerpool.com.

Larimar Therapeutics SWOT Analysis

Strengths

1. Innovative Therapies: Larimar Therapeutics Inc is known for its innovative therapies that have the potential to address currently unmet medical needs.

2. Strong Scientific Expertise: The company has a team of highly skilled scientists and researchers who are well-versed in the field of pharmaceuticals and gene therapy.

3. Intellectual Property: Larimar Therapeutics Inc possesses a strong portfolio of intellectual property, including patents and proprietary technology, which provides a significant competitive advantage.

Weaknesses

1. Limited Financial Resources: The company may face challenges in funding its research and development activities due to its limited financial resources.

2. Lack of Market Presence: Larimar Therapeutics Inc is a relatively new entrant in the market and has yet to establish a strong market presence and brand recognition.

3. Regulatory Challenges: The pharmaceutical industry is highly regulated, and compliance with strict regulatory requirements may pose a challenge for the company.

Opportunities

1. Growing Demand for Gene Therapies: With the increasing prevalence of genetic disorders, there is a growing demand for innovative gene therapies, which presents a significant opportunity for Larimar Therapeutics Inc.

2. Partnerships and Collaborations: The company can explore strategic partnerships and collaborations with other pharmaceutical companies or research institutions to expand its research capabilities and market reach.

3. Emerging Markets: Larimar Therapeutics Inc can consider expanding its operations into emerging markets where there is a rising need for advanced therapies.

Threats

1. Intense Competition: The pharmaceutical industry is highly competitive, and Larimar Therapeutics Inc may face intense competition from established players and emerging biotech companies.

2. Legal and Regulatory Risks: Changes in regulations or legal challenges related to intellectual property rights or drug approvals can pose significant risks to the company's operations.

3. Technological Advancements: Rapid advancements in technology may lead to the development of alternative treatment options, which could potentially diminish the market potential for Larimar Therapeutics Inc's therapies.

Larimar Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Larimar Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

Larimar Therapeutics shares outstanding

The number of shares was Larimar Therapeutics in 2023 — This indicates how many shares 43.901 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Larimar Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Larimar Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Larimar Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Larimar Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Larimar Therapeutics stock splits

In Larimar Therapeutics's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Larimar Therapeutics.

Larimar Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.31 -0.34  (-9.18 %)2024 Q2
3/31/2024-0.24 -0.27  (-12.64 %)2024 Q1
12/31/2023-0.25 -0.3  (-18.91 %)2023 Q4
9/30/2023-0.23 -0.21  (7.85 %)2023 Q3
6/30/2023-0.2 -0.19  (4.47 %)2023 Q2
3/31/2023-0.25 -0.15  (40.22 %)2023 Q1
12/31/2022-0.28 -0.21  (24.46 %)2022 Q4
9/30/2022-0.43 -0.37  (13.63 %)2022 Q3
6/30/2022-0.58 -0.47  (19.63 %)2022 Q2
3/31/2022-0.52 -0.49  (5.81 %)2022 Q1
1
2
3
4

Eulerpool ESG Scorecard© for the Larimar Therapeutics stock

Eulerpool World ESG Rating (EESG©)

57/ 100

🌱 Environment

59

👫 Social

81

🏛️ Governance

32

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees63
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Larimar Therapeutics shareholders

%
Name
Stocks
Change
Date
9.47399 % RA Capital Management, LP6,045,3516,045,3512/16/2024
5.35099 % Cowen Investment Management LLC3,414,46809/30/2023
5.35099 % Blue Owl Capital Holdings LP3,414,4683,414,46812/31/2023
4.40547 % Verition Fund Management LLC2,811,131-89,40712/31/2023
4.13895 % Janus Henderson Investors2,641,065179,60312/31/2023
33.27374 % Deerfield Management Company, L.P.21,231,97403/14/2024
2.40087 % BlackRock Institutional Trust Company, N.A.1,531,997162,89312/31/2023
2.28059 % The Vanguard Group, Inc.1,455,24327,51612/31/2023
2.00075 % Adage Capital Management, L.P.1,276,680100,00012/31/2023
1.26283 % Mangrove Partners805,815012/31/2023
1
2
3
4
5
...
10

Larimar Therapeutics Executives and Management Board

Dr. Carole Ben-Maimon62
Larimar Therapeutics President, Chief Executive Officer, Director (since 2020)
Compensation 2.13 M
Mr. Michael Celano64
Larimar Therapeutics Chief Financial Officer, Company Secretary
Compensation 1.13 M
Mr. Joseph Truitt58
Larimar Therapeutics Independent Chairman of the Board
Compensation 100,084
Mr. Frank Thomas53
Larimar Therapeutics Independent Director
Compensation 67,584
Mr. Jonathan Leff54
Larimar Therapeutics Independent Director
Compensation 65,084
1
2

Most common questions regarding Larimar Therapeutics

What values and corporate philosophy does Larimar Therapeutics represent?

Larimar Therapeutics Inc represents a strong commitment to developing innovative treatments for rare diseases. The company's corporate philosophy revolves around patient-centered care, scientific excellence, and collaboration. With a focus on precision medicine, Larimar Therapeutics Inc strives to improve the lives of individuals affected by rare genetic disorders. Through its dedication to research and development, the company aims to provide effective therapies that address the underlying cause of these diseases. Larimar Therapeutics Inc's vision is to redefine the standard of care and make a meaningful impact in the field of rare diseases.

In which countries and regions is Larimar Therapeutics primarily present?

Larimar Therapeutics Inc is primarily present in the United States.

What significant milestones has the company Larimar Therapeutics achieved?

Larimar Therapeutics Inc has achieved several significant milestones. The company successfully completed its initial public offering (IPO) in February 2021, raising substantial capital to fund its research and development efforts. Larimar Therapeutics Inc also established key collaborations with leading industry partners to advance its gene therapy programs for treating rare diseases. Furthermore, the company has made significant progress in its lead product candidate, CTI-1601, for treating Friedreich's ataxia, a rare genetic disease. Larimar Therapeutics Inc's dedication to developing innovative therapies and its strategic partnerships have positioned the company as a promising player in the biotechnology sector.

What is the history and background of the company Larimar Therapeutics?

Larimar Therapeutics Inc., founded in [insert year], is a biotechnology company specializing in gene therapies for rare diseases. The company's mission is to develop innovative treatments that address the underlying genetic causes of these conditions. Larimar Therapeutics Inc. has a strong focus on utilizing its proprietary gene-manipulation platform to design and deliver highly targeted therapies. By leveraging cutting-edge technologies, the company aims to improve the lives of patients with limited or no treatment options. Larimar Therapeutics Inc. continues to collaborate with leading academic institutions and pharmaceutical partners to accelerate the development of novel gene therapies and make a meaningful impact in the field of rare disease treatment.

Who are the main competitors of Larimar Therapeutics in the market?

The main competitors of Larimar Therapeutics Inc in the market include other companies in the biopharmaceutical sector, such as Amicus Therapeutics, Inc., REGENXBIO Inc., and Sangamo Therapeutics, Inc. These companies also focus on developing innovative therapies for rare genetic diseases and disorders. Larimar Therapeutics Inc distinguishes itself through its proprietary protein replacement platform and dedication to addressing unmet medical needs in rare diseases. As Larimar Therapeutics Inc continues to drive advancements in the biopharmaceutical industry, it faces competition with these prominent players who strive for similar scientific and commercial success.

In which industries is Larimar Therapeutics primarily active?

Larimar Therapeutics Inc is primarily active in the biotechnology industry.

What is the business model of Larimar Therapeutics?

The business model of Larimar Therapeutics Inc revolves around developing innovative therapies for treating rare genetic diseases. Larimar Therapeutics focuses on advancing small molecule therapeutics that target RNA using its proprietary Ribonucleic Acid Displacement (RAD) technology. This approach enables the company to modulate the mRNA translation, thereby addressing the underlying genetic cause of the diseases. By leveraging its expertise in drug discovery and development, Larimar Therapeutics aims to improve the lives of patients with rare genetic disorders through the development of targeted and effective treatments.

What is the P/E ratio of Larimar Therapeutics 2024?

The Larimar Therapeutics P/E ratio is -3.13.

What is the P/S ratio of Larimar Therapeutics 2024?

The Larimar Therapeutics P/S ratio is 0.

What is the AlleAktien quality score of Larimar Therapeutics?

The AlleAktien quality score for Larimar Therapeutics is 3/10.

What is the revenue of Larimar Therapeutics 2024?

The revenue cannot currently be calculated for Larimar Therapeutics.

How high is the profit of Larimar Therapeutics 2024?

The expected Larimar Therapeutics profit is -91.93 M USD.

What is the business model of Larimar Therapeutics

Larimar Therapeutics Inc is a biotechnology company that focuses on developing therapies for rare genetic diseases. The company utilizes modern technologies to improve treatment options for patients with rare genetic diseases who often have limited options for treating their condition. The business model of Larimar Therapeutics consists of four main areas: 1. Research and development: Larimar Therapeutics invests in the development of new therapies for rare genetic diseases. The company collaborates closely with leading scientists and clinics to develop and test new treatment possibilities. 2. Partnerships: Larimar Therapeutics aims to establish partnerships with other biotechnology and pharmaceutical companies to achieve greater reach and leverage research opportunities together. 3. Licensing: The company works with licensing technologies and products to develop new treatment options for rare genetic diseases. 4. Distribution: In terms of creating distribution channels, the company, as a biotechnology company, is not directly responsible. The end product developed by the company must be made available to an independent distributor or distribution company. The products of Larimar Therapeutics include therapies for rare genetic diseases, including: 1. Friedreich's Ataxia: Friedreich's Ataxia is a neurological metabolic disease that can lead to problems with movement, vision, and speech. Larimar Therapeutics specializes in the development of drugs targeting the causes of Friedreich's Ataxia. 2. Other inherited diseases: Larimar Therapeutics is working on developing therapies for a range of diseases, including Duchenne muscular dystrophy, Maroteaux-Lamy syndrome, and Mucopolysaccharidosis type IVA. Larimar Therapeutics utilizes state-of-the-art technologies and research methods to ensure the precision, effectiveness, and safety of their therapies while improving cost-effectiveness and the opportunity to make these treatment options accessible to everyone. The company aims to achieve a strong leadership position in the rare diseases field by developing innovative solutions and therapies to improve and enhance the lives of patients in the long term.

What is the Larimar Therapeutics dividend?

Larimar Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Larimar Therapeutics pay dividends?

The dividend cannot currently be calculated for Larimar Therapeutics or the company does not pay out a dividend.

What is the Larimar Therapeutics ISIN?

The ISIN of Larimar Therapeutics is US5171251003.

What is the Larimar Therapeutics WKN?

The WKN of Larimar Therapeutics is A2P5PP.

What is the Larimar Therapeutics ticker?

The ticker of Larimar Therapeutics is LRMR.

How much dividend does Larimar Therapeutics pay?

Over the past 12 months, Larimar Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Larimar Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Larimar Therapeutics?

The current dividend yield of Larimar Therapeutics is .

When does Larimar Therapeutics pay dividends?

Larimar Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Larimar Therapeutics?

Larimar Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Larimar Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Larimar Therapeutics located?

Larimar Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Larimar Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Larimar Therapeutics from 10/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/1/2024.

When did Larimar Therapeutics pay the last dividend?

The last dividend was paid out on 10/1/2024.

What was the dividend of Larimar Therapeutics in the year 2023?

In the year 2023, Larimar Therapeutics distributed 0 USD as dividends.

In which currency does Larimar Therapeutics pay out the dividend?

The dividends of Larimar Therapeutics are distributed in USD.

All fundamentals about Larimar Therapeutics

Our stock analysis for Larimar Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Larimar Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.